GLOW
BPC-157 + TB-500 + GHK-Cu in one vial — and the arithmetic that comes with it.
Skin & dermal · 6 min read · updated 13 Aug 2026
Research use only. The ranges below are what published studies and community protocols report. They are reference material for laboratory research, not medical advice or a recommendation for human or veterinary use.
The compound
GLOW
View- Type
- Peptide Complex
- CAS
- N/A (Proprietary Blend)
- Formula
- N/A (Composite Blend)
- Mass
- N/A (Composite Blend)
At a glance
- Class
- Three-peptide repair blend
- Composition
- BPC-157 10 mg + TB-500 10 mg + GHK-Cu 50 mg
- Total per vial
- 70 mg
- Ratio
- 1 : 1 : 5
- Vial size stocked
- 70 mg
GLOW puts three repair compounds in a single lyophilised cake, chosen because they act on different stages of the same process. BPC-157 supplies the vascular arm — angiogenesis and blood flow. TB-500 supplies the cellular arm — migration of the repair cells into the site. GHK-Cu supplies the matrix arm — collagen, elastin and glycosaminoglycan synthesis together with the remodelling enzymes that shape them.
The clinical logic is sound and the convenience is genuine. The catch is that a blend removes your ability to dose the three components independently, and the ratio is fixed at 1:1:5 by mass. Every protocol decision has to be made through that ratio.
Read the individual articles for BPC-157, TB-500 and GHK-Cu before designing a GLOW protocol — the mechanisms, cautions and evidence limits described there all carry over unchanged.
The blend arithmetic — the part worth getting right
The vial holds 70 mg total in a 1:1:5 ratio. Divide any blend dose by 7 to get the BPC-157 amount and the TB-500 amount; multiply that by 5 for the GHK-Cu amount.
Worked example: a 1.75 mg blend dose delivers 0.25 mg BPC-157, 0.25 mg TB-500 and 1.25 mg GHK-Cu. That lands BPC-157 in its standard reported daily range, GHK-Cu comfortably in its 1–2 mg range, and TB-500 at 0.25 mg daily — which is 1.75 mg a week, close to the low end of a TB-500 loading week.
The tension is structural: BPC-157 and GHK-Cu are daily compounds, while TB-500 is a twice-weekly compound. A blend cannot satisfy both cadences. Reported GLOW protocols resolve it by dosing daily and accepting that the TB-500 arm is delivered as a small daily amount rather than as large intermittent boluses. That is a defensible design, but it is not the same exposure pattern the TB-500 literature used.
Copper is the ceiling here too
GHK-Cu is 5/7ths of this blend by mass, which means the copper load governs how long a GLOW block can reasonably run. At 1.75 mg of blend daily the GHK-Cu component is 1.25 mg per day — around 0.2 mg of copper. Over a four-week block that is a meaningful cumulative addition to dietary intake, and it is the reason blocks are kept to weeks rather than months.
Storage
- Lyophilised: 2–8 °C, or −20 °C for extended storage. Protect from light — the GHK-Cu component makes this more important than for a plain peptide.
- Reconstituted: 2–8 °C, used within about 28 days. Never freeze.
Cautions
- Every caution from the three component articles applies: the angiogenesis concern from BPC-157 and TB-500, the copper accumulation concern from GHK-Cu, and the absence of controlled human trials for all three.
- A blend makes it impossible to attribute an effect — beneficial or otherwise — to one component.
- TB-500 is on the WADA prohibited list, and so, therefore, is this blend.
References & credit
- 1See the individual articles — BPC-157, TB-500 and GHK-Cu each carry their own reference list — the blend adds no new primary literature.
This article was written in-house. Where a dose range reflects community practice rather than a published trial, the community references we consulted are credited above and the article says which is which.